Emergent nanotherapies in microcrystal-induced arthritis


    loading  Checking for direct PDF access through Ovid

Abstract

The anti-inflammatory and immunomodulatory effects of nanoparticles in several chronic diseases have been extensively researched. The aim of this review is to examine how nanoparticles modulate the inflammatory pathways that characterize the most prevalent forms of microcrystal-induced arthritis, including gout, pseudogout, and BCP-induced arthritis. The nanoparticles of chitosan-coated calcium phosphate, uricase, aceclofenac, and gold have been investigated in crystal-inducedarthritis. The most important results of the studies outlined in this review show that nanoparticles can inhibit the expression and the release of some pro-inflammatory mediators and proteolytic enzymes, and the activity of different transcriptional factors in vitro, as well as decrease the uric acid levels in several studies of in vitro and in vivo models of gout, which show interesting results in terms of decreasing the amount of crystals and tissue damage, respectively. In view of their multiple beneficial effects, nanoparticles can be considered a valuable therapy that contributes to the pharmacological treatment in crystalinduced arthritis.HighlightsNPs modulate the inflammatory pathways of crystal-induced arthritis.NPs could inhibit the expression of several pro-inflammatory mediators and proteolytic enzymes in crystal-induced arthritis.NPs could induce activity of different transcriptional factors, as well as decrease uric acid levels.NPs alleviate inflammatory responses, decreasing the amount of crystals and tissue damage in gout and pseudogout.NPs can be considered a valuable therapy that contributes to the pharmacological treatment in crystal-induced arthritis.

    loading  Loading Related Articles